

# Research & Reviews: Journal of Medical and Health Sciences

## Future Prospects of Genome Sequencing

Sharma S\*

Department of Genetics, Vellore Institute of Technology, Vellore, India

### Review Article

Received date: 08/07/2016  
Accepted date: 01/08/2016  
Published date: 10/08/2016

#### \*For Correspondence

Sharma S, Department of Genetics, Vellore Institute of Technology, Vellore, India, Tel: 7731021501.

**E-mail:** mailme\_shatakshi@rediffmail.com

**Keywords:** Whole genome sequencing, Clinical trials, Chromosomal DNA, Single cell genome sequencing.

#### ABSTRACT

The shift from manual DNA sequencing methods such as Maxam-Gilbert sequencing and Sanger sequencing in the 1970s and 1980s to more rapid, automated sequencing methods in the 1990s played a crucial role in giving scientists the ability to sequence whole genomes. Almost any biological sample containing a full copy of the DNA—even a very small amount of DNA or ancient DNA—can provide the genetic material necessary for full genome sequencing. Such samples may include saliva, epithelial cells, bone marrow, hair (as long as the hair contains a hair follicle), seeds, plant leaves, or anything else that has DNA-containing cells. The genome sequence of a single cell selected from a mixed population of cells can be determined using techniques of *single cell genome sequencing*. This has important advantages in environmental microbiology in cases where a single cell of a particular microorganism species can be isolated from a mixed population by microscopy on the basis of its morphological or other distinguishing characteristics. In such cases the normally necessary steps of isolation and growth of the organism in culture may be omitted, thus allowing the sequencing of a much greater spectrum of organism genomes.

#### INTRODUCTION

Whole Genome sequencing or complete genome sequencing is a methodology describing the complete DNA game plan of a living being's genome at one time. It fuses the sequencing of the dominant part of an animal's chromosomal DNA and what's more DNA contained in the mitochondria. Genome sequencing procedures are nowadays used on an endless scale as a piece of Clinical trials and considering transformative science. Any cell can be used for genome sequencing containing a full copy of the DNA. Single cell genome sequencing choosing the genome gathering of a lone cell from a mixed people of cells has advantage in natural microbiology too. Pre-implantation inherited finding in like manner consolidates single cell genome sequencing.

#### TECHNIQUES USED AS A PIECE OF SEQUENCING

Earlier the most surely understood methodology for sequencing was shotgun sequencing which consolidates sequencing of one end yet it was comprehended that that profitable information can be expelled by sequencing both the terminations however nowadays whole genome sequencing with the help of chip <sup>[1-10]</sup>, PCs and Information age to store the tremendous genomic data electronically making the entire cumbersome technique of sequencing much too much less requesting.

Sanger sequencing was similarly used as a part of past used to choose the innate code yet since it was a period eating up and exorbitant procedure it is not regularly used as a piece of labs. Likewise simply short bits of DNA can be sequenced through it. Front line sequencing is particularly looked for after these days as it can plan greater bits of DNA <sup>[11-18]</sup>. It allows the unmistakable evidence of assortment in protein-coding district of any quality instead of few picked qualities. Change usually happens in the exons and thusly using whole exome sequencing we can recognize the possible contamination realizing changes easily in restricted capacity to concentrate almost at a lesser cost. Exactly when DNA assortments happens outside the exons then it can affect the entire quality activity and protein era finally inciting innate messes which can't be recognized by whole exome sequencing <sup>[19-28]</sup>.

Nowadays Nano pore and fluorescence Innovation is likewise been utilized on a huge scale. Cutting edge sequencing (NGS) permits to adequately performing entire genome sequencing (WGS) that may prompt the presentation of new genome-based investigations into clinical practice. WGS is one of not very much late advancement in pharmaceutical which are portrayed by the qualities 'better', "speedier" and 'less expensive'. NGS dependably includes non-coordinated mass sequencing [29-36].

Confinement of sequencing on a genomic locale, a board of qualities, or the exome (all protein-coding exons), for case, can be accomplished by a catching instrument taking into account hybridizing oligonucleotides that characterize the arrangement zone [37-42]. The use of NGS for the examination of RNAs ('transcriptome') or epigenetic alterations ('methylome') is direct. NGS guarantees almost boundless conceivable outcomes to hunt down hereditary variations with clinical pertinence. This incorporates the location of established and additionally of substantial changes as reasons for monogenic infections, the all-inclusive task of danger scores for polygenic sicknesses, the recognizable proof of tumor-or metastasis-particular transformations in individual tumor patients and the determination of quality expression profiles (marks) with prognostic and/or restorative significance [43-56].

## ADVANTAGES OF ENTIRE GENOME SEQUENCING

The WGS study affirmed known issues of WGS/WES examinations in unselected/solid people: constrained affectability for a few classes of transformations, for example, auxiliary variations, high false-positive rates in mechanized translation, high time necessity for expert curation and a generally low effect on medicinal consideration. Making customized arrangements to treat malady might be conceivable construct not just in light of the mutant qualities bringing on an infection, additionally different qualities in the patient's genome [57-69].

Genotyping malignancy cells and understanding what qualities are misregulated permits doctors to choose the best chemotherapy and conceivably open the patient to less harmful treatment since the treatment is custom fitted. Beforehand obscure qualities might be distinguished as adding to an illness state. Conventional hereditary testing takes a gander at the regular "troublemaker" qualities.

Way of life or natural changes that can intervene with the impacts of hereditary inclination might be recognized and after that directed [70-90]. Catches both huge and little variations that may some way or another be missed and Recognizes potential causative variations for further take after on investigations of quality expression and direction systems [91-96].

## CONCLUSION

We can infer that entire genome sequencing grows indicative utility and enhances clinical administration in paediatric solution. WGS surpasses other innovation stages in capacity to recognize hereditary variations required in adolescence malady. Expanded symptomatic utility of WGS can significantly affect clinical consideration and administration that goes past hereditary advising. NGS innovations have effectively had an emotional effect on the field of Microbiology. Notwithstanding giving more financially savvy sequencing techniques, the scope of utility-based applications, which stretched out past the first extension of NGS advancements, will take into account a more exact practical explanation of microbial genomes Momentum and future NGS advances guarantee to give new bits of knowledge into individual microbial genomes, the structure of the groups they possess, and their effect on human wellbeing malady. This thusly will take into account the improvement of more precise models of sickness and contamination and result in the advancement of another scope of symptomatic devices and therapeutics to battle irresistible illness.

## REFERENCES

1. Ebbesen M, et al. A philosophical analysis of informed consent for whole genome sequencing in biobank research by use of Beauchamp and Childress's four principles of biomedical ethics. *J Clin Res Bioeth.* 2015;6:244.
2. Ahmed I. Chloroplast genome sequencing: some reflections. *Next Genat Sequenc & Applic.* 2015;2:119.
3. Dhama N and Sharma N. Genome sequencing: Future prospective. *Res J Biol.* 2015;3:119.
4. Dhillon V and Li X. Single-cell genome sequencing for viral-host interactions. *J Comput Sci Syst Biol.* 2015;8:160-165.
5. Gryganskyi AP and Muszewska A. Whole genome sequencing and the zygomycota. *Fungal Genom Biol.* 2014;4: e116.
6. Cooper WG. Quantum information processing model explains Early and Recent genome repair mechanisms. *Pure and Applied Physics.*
7. Li J, et al. Effects of microgravity on the phenotype, genome and transcriptome of *Streptococcus pneumoniae*. *Journal of Microbiology and Biotechnology.* 2016.
8. Niculescu VF. Pathogenicity of entamoeba species depends on cell line conversion, genome reprogramming and epigenetic gene regulation. *J Cell Sci Ther* 2016;7:245.
9. Zhang Y. On the use of P-values in genome wide disease association mapping. *J Biom Biostat.* 2016;7:297.

10. Gómez-Manjón I, et al. Non-invasive prenatal detection of a partial trisomy 4 using whole genome semiconductor sequencing. *J Genet Syndr Gene Ther.* 2016.
11. Loyola DE, et al. Genealogy of the genome components in the highly homogeneous pandemic *Vibrio parahaemolyticus* population. *J Phylogen Evolution Biol.* 2016;4:165.
12. Popa-Wagner A and Buga AM. Identification of new therapeutic targets for cerebral ischemia by genome-wide analysis. *Biochem Anal Biochem.* 2016,5:e162.
13. Farooqi MS, et al. Genome-wide relative analysis of codon usage bias and codon context pattern in the bacteria *Salinibacter ruber*, *Chromohalobacter salexi*.
14. Refolo MG, et al. Modulation of doxorubicin actions in hepatocellular carcinoma cells by insulin-like growth factor-I. *Biochem Anal Bioche.* 2016.
15. Arumugam S and Jayandharan GR. Adeno-associated virus (AAV)-2 genome in *Arthrobacter* sp. LS16? *J Genet Syndr Gene Ther.* 2016;7:293.
16. Liu Y and Zheng J. Variant maps to identify coding and non-coding DNA sequences of genomes selected from multiple species. *Biol Syst Open Access.* 2016;5:153.
17. Rodriguez E. Ethical issues in genome editing using Crispr/Cas9 system. *J Clin Res Bioeth.* 2016;7:266.
18. Hou X, et al. Composition and variation analysis of the TCR-chain CDR3 repertoire in systemic lupus erythematosus using high-throughput sequencing by Sui. *Immunogenet Open Access.* 2016.
19. Kothari R, et al. Application of next generation sequencing technologies in revealing plant-Microbe interactions. *Next Generat Sequenc & Applic.* 2016;3:e108.
20. Taller J, et al. *De novo* transcriptome sequencing based identification of Amb a 3-like pollen allergen in common ragweed. *Ambrosia Artem.* 2016.
21. Ferber MJ, et al. Clinical validation of a next generation sequencing panel test for hereditary colorectal cancer. *J Med Diagn Meth.* 2016.
22. Kotecki N, et al. Contribution of next-generation sequencing in a case of metastatic breast carcinoma with pulmonary lesions. *J Lung Cancer Diagn Treat.* 2016;1:103.
23. Chandramouli K. The importance of next-generation sequencing for marine larvae research: Insight into larvae settlement and anti-fouling. *J Data Mining Genomics Proteomics.* 2016;7:2.
24. Ashktorab H, et al. Targeted exome sequencing outcome variations of colorectal tumors within and across two sequencing platforms. *Next Generat Sequenc & Applic.* 2016;3:123.
25. Ibrahim M and Musa M. Effective size and effectiveness: Next generation sequencing and the practice of genomics in Africa. *Next Generat Sequenc & Applic.* 2016;S1:008.
26. Liu J, et al. Fusion genes and their detection through next generation sequencing in malignant hematological disease and solid tumors. *Diagn Pathol Open.* 2015;1:108.
27. Ye K, et al. Structural variation detection from next generation sequencing. *Next Generat Sequenc & Applic.* 2016;S1:007.
28. Attia TH and Saeed MA. Next generation sequencing technologies: A short review. *Next Generat Sequenc & Applic.* 2016;S1:006.
29. Ansorge WJ. Next generation DNA sequencing (II): Techniques, applications. *Next Generat Sequenc & Applic.* 2016;S1:005.
30. Suma J and Sivakumar G. Next generation sequencing-current status. *Next Generat Sequenc & Applic.* 2016;3:e107.
31. Ku CS. Bringing next-generation sequencing oncology tests into the diagnostic setting. *Next Generat Sequenc & Applic.* 2016;S1:004.
32. De Mandal S, et al. Microbial ecology in the era of next generation sequencing. *Next Generat Sequenc & Applic.* 2015;S1:001.
33. Qichang Wu, et al. Detection of copy number variants by next-generation sequencing in fetuses with congenital heart disease. *Gynecol Obstet (Sunnyvale).* 2016;6:35.
34. Sahu J and Talukdar AD. Big next generation sequencing data. *Transcriptomics.* 2015;3:121.
35. Meller R. Addressing benefits, risks and consent in next generation sequencing studies. *J Clin Res Bioeth.* 2015;6:249.
36. Plummer E, et al. A comparison of three bioinformatics pipelines for the analysis of preterm gut microbiota using 16S rRNA gene sequencing data. *J Proteomics Bioinform.* 2015;8:283-329.
37. Le HT, et al. Development of sequencing batch reactor performance for nitrogen wastewater treatment. *J Microb Biochem Technol.* 7:363-366.

38. Zhang Y, et al. Whole-exome sequencing identifies novel somatic mutations in Chinese breast cancer patients. *J Mol Genet Med.* 2015;9:183.
39. Ebbesen M, et al. A philosophical analysis of informed consent for whole genome sequencing in biobank research by use of Beauchamp and Childress's four principles of biomedical ethics. *J Clin Res Bioeth.* 2015.
40. Marzooq Ammar AL. Discovery of novel DNA variants in Jordanians population by re-genotyping Affymetrix DMET arrays data using DNA sequencing. *Biol.* 2015;4:3.
41. Cai ZX, et al. APC, FBXW7, KRAS, PIK3C. 2014.
42. Sharma S. Detection of mutations in rpoB gene of clinically isolated *M. tuberculosis* by DNA sequencing. *J Mycobac Dis.* 2014;4:156.
43. Sun Q, et al. Diagnostic direct DNA sequencing and systemic treatment with voriconazole in *Scedosporium apiospermum* Keratitis? A case report. *J Clin Exp Ophthalmol.* 2013;4:299.
44. Krstic PS. Challenges in third-generation DNA sequencing. *J Nanomed Nanotechnol.* 2012;3:e116.
45. Lu C and Yu P. Biological and solid-state nanopores for DNA sequencing. *Biochem & Pharmacol.* 2012;1: e109.
46. Neil AM, et al. Management of high-throughput DNA sequencing projects: Alpheus J. 2008.
47. Gómez-Manjón I, et al. Non-invasive prenatal detection of partial trisomy 4 using whole genome semiconductor sequencing. *J Genet Syndr Gene Ther.* 2016.
48. Blum HE, et al. Clinical interpretation and implications of whole genome sequencing. *Next Generat Sequenc & Applic.* 2014;1:105.
49. Jaiswal M and Pandey A. *In silico* mining of simple sequence repeats in whole genome of *Xanthomonas* sp. *J Comput Sci Syst Biol.* 2014;7:203-208.
50. Gryganskyi AP and Muszewska A. Whole genome sequencing and the zygomycota. *Fungal Genom Biol.* 2014;4:e116.
51. Hu W, et al. Scanning QTLs for grain shape using a whole genome SNP array in rice. *J Plant Biochem Physiol.* 2013;1:104.
52. Cooper WG. Quantum information processing model explains Early and Recent genome repair mechanisms. *Pure and Applied Physics.*
53. Li J, et al. Effects of microgravity on the phenotype. Genome and transcriptome of *Streptococcus pneumoniae*. *Journal of Microbiology and Biotechnology.* 2016.
54. Niculescu VF. Pathogenicity of entamoeba species depends on cell line conversion, genome reprogramming and epigenetic gene regulation. *J Cell Sci Ther.* 2016;7:245.
55. Zhang Y. On the use of P-values in genome wide disease association mapping. *J Biom Biostat.* 2016;7:297.
56. Loyola DE, et al. Genealogy of the genome components in the highly homogeneous pandemic *Vibrio parahaemolyticus* population. *J Phylogen Evolution Biol.* 2016;4:165.
57. Popa-Wagner A and Buga AM. Identification of new therapeutic targets for cerebral ischemia by genome-wide analysis. *Biochem Anal Biochem.* 2016;5:e162.
58. Farooqi MS, et al. Genome-wide relative analysis of codon usage bias and codon context pattern in the bacteria *Salinibacter ruber*, *Chromohalobacter salexi*. 2016.
59. Refolo MG, et al. Modulation of doxorubicin actions in hepatocellular carcinoma cells by insulin-like growth factor-I. *Biochem Anal Bioche.* 2016.
60. Arumugam S and Jayandharan GR. Adeno-associated virus (AAV)-2 genome in *Arthrobacter* sp. LS16? *J Genet Syndr Gene Ther.* 2016;7:293.
61. Rodriguez E. Ethical issues in genome editing using Crispr/Cas9 system. *J Clin Res Bioeth.* 2016;7:266.
62. Xiao X, et al. The complete mitochondrial genome and phylogenetic analysis of Chinese Jianchang Horse (*Equus caballus*). *Clon Transgen.* 2015;5:149.
63. Zhang Y, et al. The complete chloroplast genomes of Asteraceae species. *Journal of Botanical Sciences.* 2016.
64. Sharma N, et al. Genome sequence information in fruit crops: Current status. *Transcriptomics.* 2016;4:130.
65. Kachroo S and Gowder SJT. Human genome - Underlying scientific mysteries. *J Socialomics.* 2016;5:157.
66. Manesh DM and Malik P. The current state-of-the-art in therapeutic genome editing and the future. *Gene Technol.* 2016;5:135.
67. Nair RG, et al. Genome mining and comparative genomic analysis of five coagula.

68. Rance E, et al. A method for *in situ* localization of single-strand and double-strand RNA elements contained in the hepatitis C virus genome 3'-untranslated region. *Adv Tech Biol Med.* 2015;3:171.
69. Vyas G, et al. Evaluation of next generation sequencing platforms for whole exome variant analysis. *Clin Med Biochemistry Open Access.* 2016;1:112.
70. Banerjee HN, et al. Molecular diagnosis of *Helicobacter pylori* strain by 16S rDNA PCR amplification and direct sequencing. *J Bioprocess Biotechniq.* 2011;1:105e.
71. van den Toorn HWP, et al. Targeted SCX based peptide fractionation for optimal sequencing by collision induced and electron transfer dissociation. *J Proteomics Bioinform.* 2008;1.8:37.
72. Xu J, et al. The FDA's experience with emerging genomics technologies-past, present and future. *AAPS J.* 2016;18:814-818.
73. Flannery EL, et al. Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. *ACS Chem Biol.* 2015.
74. Harris KK, et al. Novel imidazoline antimicrobial scaffold that inhibits DNA replication with activity against mycobacteria and drug resistant Gram-positive cocci. *ACS Chem Biol.* 2014;9:2572-2583.
75. Schorn M, et al. Genetic basis for the biosynthesis of the pharmaceutically important class of epoxyketone proteasome inhibitors. *ACS Chem Biol.* 2014;9:301-319.
76. Stanley SA, et al. Identification of novel inhibitors of *M. tuberculosis* growth using whole cell based high-throughput screening. *ACS Chem Biol.* 2012;7:1377-1384.
77. Molohon KJ, et al. Plantazolicin is an ultra-narrow spectrum antibiotic that targets the *Bacillus anthracis* membrane. *ACS Infect Dis.* 2016;2:207-220
78. Flannery EL, et al. Next-generation sequencing of *Plasmodium vivax* patient samples shows evidence of direct evolution in drug-resistance genes. *ACS Infect Dis.* 2015;1:367-379.
79. Zhan C, et al. Identification of reference genes for qRT-PCR in human lung squamous-cell carcinoma by RNA-Seq. *Acta Biochim Biophys Sin (Shanghai).* 2014;46:330-337.
80. Jura J, et al. Regulatory mechanisms of gene expression: Complexity with elements of deterministic chaos. *Acta Biochim Pol.* 2006;53:1-10.
81. Błazewicz J, et al. Assembling the sars-cov genome – new method based on graph theoretical approach. *Acta Biochim Pol.* 2004;51:983-993.
82. Frank K, et al. Complete mitochondrial genome sequence of a Hungarian red deer (*Cervus elaphus hippelaphus*) from high-throughput sequencing data and its phylogenetic position within the family Cervidae. *Acta Biol Hung.* 2016;67:133-147.
83. Shaibullah S, et al. Crystallization and preliminary crystallographic studies of the hypothetical protein BPSL1038 from *Burkholderia pseudomallei*. *Acta Crystallogr F Struct Biol Commun.* 2014;1:1697-1700.
84. Farina M, et al. Is having clonal cytogenetic abnormalities the same as having leukaemia. *Acta Haematol.* 2016;135:39-42.
85. Dóro R, et al. Equine-like G3 rotavirus in Hungary - Is it a novel intergenogroup reassortant pandemic strain? *Acta Microbiol Immunol Hung.* 2016;63:243-255.
86. Marton S. Ubiquiter circovirus sequences raise challenges in laboratory diagnosis: The case of honey bee and bee mite, reptiles and free living amoebae. *Acta Microbiol Immunol Hung.* 2015;62:57-73.
87. Skvortsov TA, et al. *Mycobacterium tuberculosis* transcriptome profiling in mice with genetically different susceptibility to tuberculosis. *Acta Naturae.* 2013;5:62-69.
88. Kuo HC, et al. Novel mutations at carboxyl terminus of CIC-1 channel in myotonia congenita. *Acta Neurol Scand.* 2006;113:342-346.
89. Tzoulis C, et al. Mitochondrial DNA depletion in progressive external ophthalmoplegia caused by POLG1 mutations. *Acta Neurol Scand Suppl.* 2009;189:38-41.
90. Ichimura K, et al. Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. *Acta Neuropathol.* 2016;13:889-901.
91. Rivera B, et al. Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. *Acta Neuropathol.* 2016;131:847-863.
92. Qaddoumi I, et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1 and MYB mutations occur at high frequency and align with morphology. *Acta Neuropathol.* 2016 131:833-845.
93. Fukumura K, et al. Genomic characterization of primary central nervous system lymphoma. *Acta Neuropathol.* 2016;131:865-875.
94. Collins VP, et al. Pilocytic astrocytoma: Pathology, molecular mechanisms and markers. *Acta Neuropathol.* 2015;129:775-788.

95. Pottier C, et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. *Acta Neuropathol.*2015;130:77-92.
96. Hutter S, et al. Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. *Acta Neuropathol.* 2014;128:449-452. Hutter S, et al. Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. *Acta Neuropathol.* 2014;128:449-452